The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.
Juan Manuel Sepúlveda
Research Funding - Pfizer
M. Angeles Vaz
No relevant relationships to disclose
Aurelio Hernandez-Lain
No relevant relationships to disclose
Miquel Gil
No relevant relationships to disclose
Pilar Sanhez
No relevant relationships to disclose
Ramos Ana
No relevant relationships to disclose
Oscar Gallego
No relevant relationships to disclose
Gaspar Reynes
No relevant relationships to disclose
Maria Victoria Bolós
Employment or Leadership Position - Pfizer
Raquel Luque
No relevant relationships to disclose
M. Quindos
No relevant relationships to disclose
Maria Martinez Garcia
No relevant relationships to disclose
Pedro Pérez Segura
No relevant relationships to disclose
Manuel Benavides
No relevant relationships to disclose
Carmen Balañá
No relevant relationships to disclose